Advancing Care in HER2-Negative Early Breast Cancer: Essential Insights and Best Practices for Oncology Pharmacists

This activity was originally presented at the 2025 HOPA Annual Conference in Portland, Oregon.

Program Description

Improved awareness and screening, along with the use of neoadjuvant and adjuvant therapies, have led to a decrease in mortality rates for breast cancer. New targeted therapies have expanded the available treatment options for early-stage breast cancer, though their integration into therapy can be complicated by disease subtype. This session will explore specific factors that may influence treatment decision-making within current treatment guidelines for early-stage breast cancer. Informed interventions can improve treatment decision-making and adherence to therapies, resulting in fewer adverse effects, lower rates of treatment discontinuation, and reduced hospitalizations and mortality for patients. Featured patient case discussions will incorporate challenges oncology pharmacists may encounter when preparing treatment plans for patients with early-stage breast cancer, such as identification of high-risk features, treatment sequencing, and personalization of treatment regimens based on risk assessments.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: April 17, 2025
Expiration date: April 17, 2026

Time to complete activity: 1.0 hours

Learner level: Advanced
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Identify patients with early-stage HER2-negative breast cancer who may benefit from novel neoadjuvant or adjuvant treatments based on their risk of recurrence
• Factor safety and efficacy data as well as patient-specific factors into personalized treatment plans for HER2-negative early-stage breast cancer
• Employ strategies to enhance efficacy, tolerability, and adherence to neoadjuvant and adjuvant targeted and immunotherapies for patients with HER2-negative breast cancer

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-25-106-H01-P. The activity is available for CE credit through April 17, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Danielle Roman, PharmD, BCOP​, has the following financial relationships with commercial interests to disclose:
Advisory Board: Astellas, Daiichi Sankyo, Genentech

Rose DiMarco, PharmD, BCPS, BCOP, has the following financial relationships with commercial interests to disclose:
Consultant: Acclinate, CE Synergy’s Peak Exchange Clinical Thought Leader, Gilead, Lilly, Pharmacy and Healthcare Communications

Speakers Bureau: Lilly

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Julia Ziegengeist, PharmD, BCOP

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Amy L. Morris, PharmD; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms